You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Title |
An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023
|
|---|---|
| Published in |
BMC Cancer, July 2018
|
| DOI | 10.1186/s12885-018-4505-4 |
| Pubmed ID | |
| Authors |
Tadahiro Shoji, Shinichi Komiyama, Junzo Kigawa, Hiroshi Tanabe, Kazuyoshi Kato, Hiroaki Itamochi, Hiroyuki Fujiwara, Shoji Kamiura, Tetsutaro Hamano, Toru Sugiyama, for the Japanese Gynecologic Oncology Group |
Mendeley readers
The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 49 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 10 | 20% |
| Researcher | 5 | 10% |
| Student > Postgraduate | 4 | 8% |
| Student > Master | 4 | 8% |
| Other | 3 | 6% |
| Other | 6 | 12% |
| Unknown | 17 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 33% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
| Biochemistry, Genetics and Molecular Biology | 3 | 6% |
| Sports and Recreations | 3 | 6% |
| Business, Management and Accounting | 2 | 4% |
| Other | 2 | 4% |
| Unknown | 20 | 41% |